Biogen Inc. (BIIB)

227.67
NASDAQ : Health Technology
Prev Close 231.26
Day Low/High 226.96 / 231.42
52 Wk Low/High 216.12 / 388.67
Avg Volume 2.55M
Exchange NASDAQ
Shares Outstanding 193.89M
Market Cap 44.84B
EPS 21.60
P/E Ratio 9.97
Div & Yield N.A. (N.A)

Latest News

Ups and Downs on the Way

Expect a bout of volatility next week as we straddle between oversold and overbought.

Rally? What Rally?

Tuesday's rise disappointed, but any downside from here should bring on negative sentiment while we’re oversold, which should give us a real rally.

Real Money Post-Industrial Average Leaves Major Indices in the Dust

Real Money Post-Industrial Average Leaves Major Indices in the Dust

RMPIA outperformed once gain during April.

Breakthrough Tuesday

New highs grow on the New York Stock Exchange and the Investor Intelligence bulls finally tops 55%.

Feels Like Deja Tuesday

Friday felt a lot like Tuesday -- in that it didn’t change any of the big indicators -- but we should still pay close attention to the Citigroup Panic/Euphoria Index, which is now kissing the underside of Euphoria.

Cramer's Takeaways for Ford, Chevron, Alibaba, Biogen, Visa

Cramer's Takeaways for Ford, Chevron, Alibaba, Biogen, Visa

What are the main takeaways from Chevron, Ford and others? Cramer explains.

Jim Cramer Responds to Elon Musk, Talks Intel, Chevron, Ford and More

Jim Cramer Responds to Elon Musk, Talks Intel, Chevron, Ford and More

Need a road map to close out this week on Wall Street? Jim Cramer breaks down everything investors need to know about the markets from Chevron to Intel.

Jim Cramer Responds to Elon Musk, Talks Intel, Chevron, Ford and More

Jim Cramer Responds to Elon Musk, Talks Intel, Chevron, Ford and More

Need a road map to close out this week on Wall Street? Jim Cramer breaks down everything investors need to know about the markets from Chevron to Intel.

Investing's Not a Game: Cramer's 'Mad Money' Recap (Thursday 4/25/19)

Investing's Not a Game: Cramer's 'Mad Money' Recap (Thursday 4/25/19)

Jim Cramer says it's the start CNBC's annual Stock Draft Contest, but he cautions Mad Money viewers that although investing can be fun, it requires discipline and doing your homework.

Jim Cramer: My Bet's on the 'Ladies' in This Year's Draft

Jim Cramer: My Bet's on the 'Ladies' in This Year's Draft

Analyzing this year's stock draft contest and individual stock-picking vs. indexing.

Biogen Shares Fall After Drugmaker Meets Earnings Estimates

Biogen Shares Fall After Drugmaker Meets Earnings Estimates

The stock dips after the drugmaker beats quarterly revenue estimates and earnings meet forecasts.

Netflix Taking a Knife to a Gunfight with Disney, Apple, Plus Bitcoin

Netflix Taking a Knife to a Gunfight with Disney, Apple, Plus Bitcoin

Bitcoin, the most famous of all crypto-currencies, has enjoyed something of a rebound of late.

Boeing, Snap, Texas Instruments, Microsoft and Facebook - 5 Things You Must Know

Boeing, Snap, Texas Instruments, Microsoft and Facebook - 5 Things You Must Know

U.S. stock futures are mixed, following record highs on Wall Street, as investors pause ahead of another wave of corporate earnings reports; Snap's first-quarter revenue beat expectations and the social media company reports a narrower-than-expected loss; Texas Instruments cautions that a much-anticipated rebound in global semiconductor demand could be delayed into the early half of next year.

Patients Living With Spinal Muscular Atrophy (SMA) In The Province Of Saskatchewan Gain Access To SPINRAZA™ (nusinersen)

Patients Living With Spinal Muscular Atrophy (SMA) In The Province Of Saskatchewan Gain Access To SPINRAZA™ (nusinersen)

The Government of the province of Saskatchewan has informed treating physicians that it will grant access to SPINRAZA™ to patients living with Spinal Muscular Atrophy (SMA) Saskatchewan is the second province after the province of Quebec to grant broad...

10 Speculative Stock Plays in the Biotech Sector

10 Speculative Stock Plays in the Biotech Sector

For investors interested in biotech, there's a lot to choose from, with options ranging from startups with potentially blockbuster new treatments to companies those that have been around the block a few times.

Are These Stocks the Best of the Best?

Are These Stocks the Best of the Best?

Screening Goldman Sachs' list of the top 20 stocks to see which ones are the best technical opportunities.

Stepping Carefully Into the Second Quarter

Stepping Carefully Into the Second Quarter

The potential for so-so earnings results among the S&P 500 and an initial lackluster response to IPOs could cause investors to pause a bit after a strong first three months of 2019.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ACB, ECHO, EPAY, HMTV, MYOK, NVDA, PFIE, TGE, TU Downgrades: BIIB, HBB, KEQU, MGYR, OBCI, OLP, PTMN Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

How I Use Options to Mitigate Risk and Create Income

How I Use Options to Mitigate Risk and Create Income

Buy-write strategies give you confidence to 'buy the dip' while also adding an extra income stream.

Future Brightens for 2 Small Biotech Stocks

Future Brightens for 2 Small Biotech Stocks

The biotech sector isn't for the faint of heart, but these two companies issued promising news this week.

Dow Ends Slightly Higher Despite Slowing Global Growth Worries

Dow Ends Slightly Higher Despite Slowing Global Growth Worries

The Dow Jones Industrial Average trades lower over fears on Wall Street of slowing global growth.

Biogen Announces $5 Billion Buyback Just Days After Stock Plunge

Biogen Announces $5 Billion Buyback Just Days After Stock Plunge

Biogen's board approves a share buyback program days after revealing a phase III trial of a promising Alzheimer's drug is being shelved.

Dow Ends Solidly Higher as Investors Shrug Off Fed Warning of Slowing Growth

Dow Ends Solidly Higher as Investors Shrug Off Fed Warning of Slowing Growth

Stocks are higher Thursday with the Dow up on strength in Apple.

Should You Buy the Biogen Dip?

Should You Buy the Biogen Dip?

Biogen shares are plunging almost 30% Thursday. Is this a screaming buy opportunity or a giant red flag?

Biogen May Shed $18 Billion in Value After Scrapping Alzheimer's Drug Trial

Biogen May Shed $18 Billion in Value After Scrapping Alzheimer's Drug Trial

Biogen shares plunge Thursday, wiping nearly $20 billion in value from the biotech group, after it dropped a late-stage trial for a key Alzheimer's disease drug.

Powell and Company Can Influence the Macro, but Not the Micro

Powell and Company Can Influence the Macro, but Not the Micro

All the money in the world cannot change the fact that rising stock prices and falling earnings make the market more expensive.

TheStreet Quant Rating: C (Hold)